Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025

Rhea-AI Summary

Sagimet Biosciences (Nasdaq: SGMT) will present Phase 2b FASCINATE-2 secondary analyses showing that denifanstat produced a ≥2-stage fibrosis improvement in F3 MASH patients and improved fibrosis and biomarkers in qFibrosis stage 4 MASH patients.

The data, described as showing a robust anti-fibrotic effect by conventional and AI-based digital pathology and improved non-invasive test biomarkers in a qF4 subpopulation, was selected as a Poster of Distinction for AASLD—The Liver Meeting 2025 on November 10, 2025 in Washington, DC; presenting author is Rohit Loomba, M.D., M.H.Sc.

SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that analyses of the Phase 2b FASCINATE-2 study showing that denifanstat elicited fibrosis improvement in patients with advanced fibrosis will be presented at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting^® 2025, taking place November 7-11, 2025 in Washington, DC.

This abstract has been selected as a Poster of Distinction, and the details are as follows:

Title:	Denifanstat elicited a significant ≥2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of phase 2b FASCINATE-2 study
Session:	MASLD/MASH - Therapeutics: New Agents and Approved/Available Agents ("4001-4103")
Date:	November 10, 2025, 8:00 am - 5:00 pm ET
Location:	Walter E. Washington Convention Center, Hall DE (Posters and Exhibits), Level 2
Presenting author:	Rohit Loomba, M.D., M.H.Sc., University of California San Diego

The analysis showed denifanstat's robust anti-fibrotic effect as measured by both conventional and AI-based digital pathology. AI-based digital pathology was utilized to identify a subpopulation of MASH patients with advanced baseline fibrosis (qF4) and enabled the observation that denifanstat reduced fibrosis and improved multiple non-invasive test (NIT) biomarkers associated with the primary drivers of MASH in this subgroup.

About Sagimet Biosciences 

Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into further development. Sagimet has recently initiated a Phase 1 pharmacokinetic (PK) clinical trial of a combination of denifanstat and resmetirom that is planned to be developed for patients living with MASH. Sagimet has also initiated a Phase 1 first-in-human clinical trial with a second oral FASN inhibitor drug candidate, TVB-3567, that is planned to be developed for acne for the U.S. For additional information about Sagimet, please visit www.sagimet.com.

About MASH

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive and severe liver disease which is estimated to impact more than 265 million people worldwide. MASH is characterized by the build-up of fat in the liver and various degrees of inflammation and fibrosis along with systemic metabolic changes including dyslipidemia (increased fat levels in blood) and insulin resistance. Patients with moderate to severe disease who have advanced fibrosis (F3) or cirrhosis (F4) have the highest risk of liver-related outcomes such as decompensation, hepatocellular carcinoma, and liver transplantation. There are few approved treatments for non-cirrhotic MASH (stages F1, F2 and F3 fibrosis) and no approved treatments for MASH cirrhosis (F4).

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding: the expected timing of the presentation of data from ongoing clinical trials, Sagimet’s clinical development plans and related anticipated development milestones, Sagimet’s cash and financial resources and expected cash runway are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause Sagimet’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, these statements can be identified by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions.

The forward-looking statements in this press release are only predictions. Sagimet has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Sagimet believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Sagimet’s control, including, among others: the clinical development and therapeutic potential of denifanstat, TVB-3567 or any other drug candidates or combination therapies Sagimet may develop; Sagimet’s ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines; Sagimet’s relationship with Ascletis, and the success of its development efforts for denifanstat; the accuracy of Sagimet’s estimates regarding its capital requirements; and Sagimet’s ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of Sagimet’s most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in these forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, Sagimet operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Sagimet may face. Except as required by applicable law, Sagimet does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Investor Contact:
Joyce Allaire 
LifeSci Advisors 
JAllaire@LifeSciAdvisors.com

Media Contact:
Michael Fitzhugh
LifeSci Advisors 
mfitzhugh@lifescicomms.com

FAQ

What will Sagimet (SGMT) present at AASLD—The Liver Meeting 2025?

Sagimet will present secondary analyses from the Phase 2b FASCINATE-2 study showing denifanstat's fibrosis improvements in F3 and qFibrosis stage 4 MASH patients.

When and where will Sagimet's SGMT poster be presented at AASLD 2025?

The Poster of Distinction will be presented on November 10, 2025 at Walter E. Washington Convention Center, Hall DE, during the MASLD/MASH therapeutics session.

Who is presenting Sagimet's FASCINATE-2 data at the AASLD meeting?

The presenting author is Rohit Loomba, M.D., M.H.Sc. from University of California San Diego.

What endpoints did Sagimet report for denifanstat in the FASCINATE-2 analysis?

The analysis reported a ≥2-stage fibrosis improvement in F3 patients and fibrosis reduction plus improved NIT biomarkers in qFibrosis stage 4 patients.

How was denifanstat's anti-fibrotic effect measured in the SGMT presentation?

Effects were measured by conventional pathology and AI-based digital pathology, which identified a qF4 subpopulation showing fibrosis and biomarker improvements.

Is Sagimet's FASCINATE-2 data considered notable at AASLD 2025?

Yes; the abstract was selected as a Poster of Distinction, indicating recognition by the meeting organizers.